These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37400678)

  • 1. Ponatinib delays the growth of solid tumours by remodelling immunosuppressive tumour microenvironment through the inhibition of induced PD-L1 expression.
    Barnwal A; Tamang R; Sanjeev Das ; Bhattacharyya J
    Br J Cancer; 2023 Oct; 129(6):1007-1021. PubMed ID: 37400678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma.
    Deng Z; Teng YJ; Zhou Q; Ouyang ZG; Hu YX; Long HP; Hu MJ; Mei S; Lin FX; Dai XJ; Zhang BY; Feng T; Tian XF
    World J Gastrointest Oncol; 2021 Nov; 13(11):1725-1740. PubMed ID: 34853646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 4. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
    Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
    J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ataxia telangiectasia mutated kinase inhibition promotes irradiation-induced PD-L1 expression in tumour-associated macrophages through IFN-I/JAK signalling pathway.
    Gao Y; Li Y; Lin Z; Zeng Y; Huang Z; Han L; Zhong Y; Gong Y; Wu Q; Xie C
    Immunology; 2023 Feb; 168(2):346-361. PubMed ID: 36326481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shenqi Fuzheng injection modulates tumor fatty acid metabolism to downregulate MDSCs infiltration, enhancing PD-L1 antibody inhibition of intracranial growth in Melanoma.
    Ma Y; Qi Y; Zhou Z; Yan Y; Chang J; Zhu X; Han J; Wu H; Tao Y; Fan F
    Phytomedicine; 2024 Jan; 122():155171. PubMed ID: 37925891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maprotiline Prompts an Antitumour Effect by Inhibiting PD-L1 Expression in Mice with Melanoma.
    Liang L; Li Y; Jiao Y; Zhang C; Shao M; Jiang H; Wu Z; Chen H; Guo J; Jia H; Zhao T
    Curr Mol Pharmacol; 2024; 17(1):e18761429259562. PubMed ID: 37982288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment.
    Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM
    Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAT3/NF-κB signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers/PD-L1 antibody immunomodulatory therapy in breast cancer.
    Cavalcante RS; Ishikawa U; Silva ES; Silva-Júnior AA; Araújo AA; Cruz LJ; Chan AB; de Araújo Júnior RF
    Br J Pharmacol; 2021 Jun; 178(11):2284-2304. PubMed ID: 33434950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model.
    Zhang H; Xie W; Zhang Y; Dong X; Liu C; Yi J; Zhang S; Wen C; Zheng L; Wang H
    Cancer Gene Ther; 2022 May; 29(5):456-465. PubMed ID: 34561555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-responsive lncRNA MIR155HG promotes PD-L1 expression in hepatocellular carcinoma cells by enhancing HIF-1α mRNA stability.
    Qiu J; Zhong F; Zhang Z; Pan B; Ye D; Zhang X; Yao Y; Luo Y; Wang X; Tang N
    Int Immunopharmacol; 2024 Jul; 136():112415. PubMed ID: 38850791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo.
    Xu H; Chen Y; Li Z; Zhang H; Liu J; Han J
    Eur J Pharmacol; 2022 Sep; 930():175154. PubMed ID: 35868447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.
    Noman MZ; Desantis G; Janji B; Hasmim M; Karray S; Dessen P; Bronte V; Chouaib S
    J Exp Med; 2014 May; 211(5):781-90. PubMed ID: 24778419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of hypoxia on PD-L1 expression in bladder cancer.
    Smith V; Mukherjee D; Lunj S; Choudhury A; Hoskin P; West C; Illidge T
    BMC Cancer; 2021 Nov; 21(1):1271. PubMed ID: 34819027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.
    Knopf P; Stowbur D; Hoffmann SHL; Hermann N; Maurer A; Bucher V; Poxleitner M; Tako B; Sonanini D; Krishnamachary B; Sinharay S; Fehrenbacher B; Gonzalez-Menendez I; Reckmann F; Bomze D; Flatz L; Kramer D; Schaller M; Forchhammer S; Bhujwalla ZM; Quintanilla-Martinez L; Schulze-Osthoff K; Pagel MD; Fransen MF; Röcken M; Martins AF; Pichler BJ; Ghoreschi K; Kneilling M
    Mol Cancer; 2023 Dec; 22(1):207. PubMed ID: 38102680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression.
    Fu Y; Mackowiak B; Feng D; Lu H; Guan Y; Lehner T; Pan H; Wang XW; He Y; Gao B
    Gut; 2023 Oct; 72(10):1942-1958. PubMed ID: 36593103
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.